Year: 2014
Type: article
Abstract: (Cancer Cell 26, 495–508; October 13, 2014) Following publication of this manuscript, the authors discovered some panels that had been incorrectly cropped in Figures S4H and S5V in the Supplemental Information. As a result of this error, the 0 hr time points of the top PARP-1 panel of Figure S4H, U266, the Tot-JNK and Tot-ERK panels of Figure S5V, U266, and the P-p38 panel of Figure S5V, RPMI-8226, as well as the 0 hr and 0.5 hr, DTP3, time points of the P-ERK panel of Figure S5V, RPMI-8226, were accidentally omitted from these panels. An extra time point (i.e., a 1.5 hr time point, T/I) was also accidentally included in the P-ERK panel of this figure. Due to an analogous error, the P-JNK panel of Figure S5V, RPMI-8226, was incorrectly aligned. The authors also discovered an antibody that had been erroneously omitted from the Supplemental Experimental Procedures. This antibody, anti-PARP-1 (9532S; 1:1,000), should have been included in the section “Antibodies, Reagents and Western Blots.” A corrected version of the Supplemental Information is now available online. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 InhibitorsTornatore et al.Cancer CellOctober 13, 2014In BriefNF-κB is implicated in MM and other malignancies, but it is challenging to block NF-κB only in diseased cells. Tornatore et al. identify an interaction between MKK7 and NF-κB-regulated GADD45β as a therapeutic target and develop a peptide that disrupts the complex and selectively kills MM cells. Full-Text PDF Open Access
Source: Cancer Cell
Authors: Laura Tornatore, Annamaria Sandomenico, Domenico Raimondo, Caroline Low, Alberto Rocci, Cathy Tralau-Stewart, Daria Capece, Daniel D’Andrea, Marco Bua, Eileen Boyle, Mark van Duin, Pietro Zoppoli, Albert Jaxa-Chamiec, Anil K. Thotakura, Julian Dyson, Brian A. Walker, Antonio Leonardi, Angela Chambery, Christoph Driessen, Pieter Sonneveld, Gareth Morgan, Antonio Palumbo, Anna Tramontano, Amin Rahemtulla, Menotti Ruvo, Guido Franzoso
Language: English
Topic: NF-κB Signaling Pathways
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $10,400
OpenAlex ID: W4242731663